Brief: SpringWorks Therapeutics to Present Phase 3 DeFi Trial Data of Ogsiveo in Desmoid Tumors at CTOS 2024 Meeting
07/11/2024 13:07
Nov 7 (Reuters) - SpringWorks Therapeutics Inc SWTX.O :
* SPRINGWORKS THERAPEUTICS ANNOUNCES LONG-TERM EFFICACY AND
SAFETY
DATA FROM PHASE 3 DEFI TRIAL OF OGSIVEO® (NIROGACESTAT) IN
ADULTS WITH DESMOID TUMORS TO BE PRESENTED AT THE CONNECTIVE
TISSUE ONCOLOGY SOCIETY (CTOS) 2024 ANNUAL MEETING
* SPRINGWORKS THERAPEUTICS INC - NIROGACESTAT SHOWS FURTHER
TUMOR
SIZE REDUCTIONS AND INCREASED ORR
* SPRINGWORKS THERAPEUTICS INC - MEDIAN TUMOR SIZE REDUCTION
OF
−75.8% AFTER FOUR YEARS OF NIROGACESTAT
Source text: ID:nGNX4k0mhg
Further company coverage: SWTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SpringWorks Therapeutics
See all newsBrief: Merck KGaA Completes Acquisition Of Springworks Therapeutics
Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN